Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
about
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries.Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay.
P2860
Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Results of the WIRK prospectiv ...... and other bleeding disorders.
@en
Results of the WIRK prospectiv ...... and other bleeding disorders.
@nl
type
label
Results of the WIRK prospectiv ...... and other bleeding disorders.
@en
Results of the WIRK prospectiv ...... and other bleeding disorders.
@nl
prefLabel
Results of the WIRK prospectiv ...... and other bleeding disorders.
@en
Results of the WIRK prospectiv ...... and other bleeding disorders.
@nl
P2093
P2860
P356
P1433
P1476
Results of the WIRK prospectiv ...... and other bleeding disorders.
@en
P2093
C M Kirchmaier
I Birschmann
R Klamroth
P2860
P304
P356
10.1111/HAE.12156
P577
2013-05-07T00:00:00Z